Back to: products

Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country

PrintEmail
Aug 2020 - 121 Pages - From $3,000
(Excel Data Sheet: $1,800)
Description

The report cover may be different from the image shown.

Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

Asia Pacific antibiotics market will grow by 4.1% annually with a total addressable market cap of $253.1 billion over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.
Highlighted with 32 tables and 58 figures, this 121-page report “Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Cephalosporin
• Penicillin
• Macrolides
• Fluoroquinolones
• Quinolones
• Monobactam
• Aminoglycosides
• Carbapenem
• Other Drug Classes

Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms

Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics

Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics

Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oral Administration
• Intravenous Administration
• Other Administration Routes

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Brand Antibiotics
• Generic Antibiotics

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories 
Astellas Pharma 
AstraZeneca Plc 
Bayer AG 
Bristol Myers Squibb Company 
Cipla Inc. 
Dr. Reddy’s Laboratories Ltd. 
Eli Lilly and Company 
F. Hoffmann-La Roche Ltd. 
Gilead Sciences, Inc. 
GlaxoSmithKline plc. 
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 
Mayne Pharma Group Ltd. 
MELINTA THERAPEUTICS, INC. 
Merck KGaA 
Novartis AG 
Pfizer Inc. 
Sanofi 
Sun Pharmaceutical Industries Ltd. 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on the Market 21
2.2 Major Growth Drivers 23
2.3 Market Restraints and Challenges 27
2.4 Emerging Opportunities and Market Trends 30
2.5 Porter’s Fiver Forces Analysis 34
3 Segmentation of Asia Pacific Market by Drug Class 38
3.1 Market Overview by Drug Class 38
3.2 Cephalosporin 40
3.3 Penicillin 41
3.4 Macrolides 42
3.5 Fluoroquinolones 43
3.6 Quinolones 44
3.7 Monobactam 45
3.8 Aminoglycosides 46
3.9 Carbapenem 47
3.10 Other Drug Classes 48
4 Segmentation of Asia Pacific Market by Action Mechanism 49
4.1 Market Overview by Action Mechanism 49
4.2 Cell Wall Synthesis Inhibitors 51
4.3 Mycolic Acid Inhibitors 52
4.4 RNA Synthesis Inhibitors 53
4.5 DNA Synthesis Inhibitors 54
4.6 Protein Synthesis Inhibitors 55
4.7 Other Mechanisms 56
5 Segmentation of Asia Pacific Market by Drug Origin 57
5.1 Market Overview by Drug Origin 57
5.2 Natural Antibiotics 59
5.3 Semi-synthetic Antibiotics 60
5.4 Synthetic Antibiotics 61
6 Segmentation of Asia Pacific Market by Activity Spectrum 62
6.1 Market Overview by Activity Spectrum 62
6.2 Broad-spectrum Antibiotics 64
6.3 Narrow-spectrum Antibiotics 65
7 Segmentation of Asia Pacific Market by Route of Administration 66
7.1 Market Overview by Route of Administration 66
7.2 Oral Administration 68
7.3 Intravenous Administration 69
7.4 Other Administration Routes 70
8 Segmentation of Asia Pacific Market by Drug Type 71
8.1 Market Overview by Drug Type 71
8.2 Brand Antibiotics 73
8.3 Generic Antibiotics 74
9 Asia-Pacific Market 2019-2030 by Country 75
9.1 Overview of Asia-Pacific Market 75
9.2 Japan 78
9.3 China 81
9.4 Australia 83
9.5 India 85
9.6 South Korea 87
9.7 Rest of APAC Region 89
10 Competitive Landscape 91
10.1 Overview of Key Vendors 91
10.2 New Product Launch, Partnership, Investment, and M&A 94
10.3 Company Profiles 95
Abbott Laboratories 95
Astellas Pharma 97
AstraZeneca Plc 98
Bayer AG 99
Bristol Myers Squibb Company 100
Cipla Inc. 101
Dr. Reddy’s Laboratories Ltd. 102
Eli Lilly and Company 103
F. Hoffmann-La Roche Ltd. 104
Gilead Sciences, Inc. 105
GlaxoSmithKline plc. 106
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 107
Mayne Pharma Group Ltd. 108
MELINTA THERAPEUTICS, INC. 109
Merck KGaA 110
Novartis AG 111
Pfizer Inc. 112
Sanofi 113
Sun Pharmaceutical Industries Ltd. 114
11 Investing in Asia Pacific Market: Risk Assessment and Management 115
11.1 Risk Evaluation of Asia Pacific Market 115
11.2 Critical Success Factors (CSFs) 118
Related Reports and Products 121

List of Tables:

Table 1.  Snapshot of Asia Pacific Antibiotics Market, 2019-2030 18
Table 2.  Main Product Trends and Market Opportunities in Asia Pacific Antibiotics Market 30
Table 3. Asia Pacific Antibiotics Market by Drug Class, 2019-2030, $ mn 38
Table 4. Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, $ mn 49
Table 5. Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, $ mn 57
Table 6. Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, $ mn 62
Table 7. Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, $ mn 66
Table 8. Asia Pacific Antibiotics Market by Drug Type, 2019-2030, $ bn 71
Table 9. APAC Antibiotics Market by Country, 2019-2030, $ bn 76
Table 10. Japan Antibiotics Market by Drug Class, 2019-2030, $ mn 80
Table 11. Japan Antibiotics Market by Drug Origin, 2019-2030, $ mn 80
Table 12. Japan Antibiotics Market by Route of Administration, 2019-2030, $ mn 80
Table 13. China Antibiotics Market by Drug Class, 2019-2030, $ mn 82
Table 14. China Antibiotics Market by Drug Origin, 2019-2030, $ mn 82
Table 15. China Antibiotics Market by Route of Administration, 2019-2030, $ mn 82
Table 16. Australia Antibiotics Market by Drug Class, 2019-2030, $ mn 84
Table 17. Australia Antibiotics Market by Drug Origin, 2019-2030, $ mn 84
Table 18. Australia Antibiotics Market by Route of Administration, 2019-2030, $ mn 84
Table 19. India Antibiotics Market by Drug Class, 2019-2030, $ mn 86
Table 20. India Antibiotics Market by Drug Origin, 2019-2030, $ mn 86
Table 21. India Antibiotics Market by Route of Administration, 2019-2030, $ mn 86
Table 22. South Korea Antibiotics Market by Drug Class, 2019-2030, $ mn 88
Table 23. South Korea Antibiotics Market by Drug Origin, 2019-2030, $ mn 88
Table 24. South Korea Antibiotics Market by Route of Administration, 2019-2030, $ mn 88
Table 25. Antibiotics Market in Rest of APAC by Country, 2019-2030, $ bn 90
Table 26. Abbott Laboratories: Company Snapshot 95
Table 27. Abbott Laboratories: Business Segmentation 95
Table 28. Abbott Laboratories: Product Portfolio 96
Table 29. Abbott Laboratories: Revenue, 2016-2018, $ mn 96
Table 30. Abbott Laboratories: Recent Developments 96
Table 31.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 116
Table 32. Critical Success Factors and Key Takeaways 119



List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Asia Pacific Antibiotics Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 21
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Antibiotics Market 23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Antibiotics Market 27
Figure 11. Investment Opportunity Analysis 31
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Antibiotics Market 34
Figure 13. Breakdown of Asia Pacific Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%) 39
Figure 15. Asia Pacific Antibiotics Market: Cephalosporin, 2019-2030, $ mn 40
Figure 16. Asia Pacific Antibiotics Market: Penicillin, 2019-2030, $ mn 41
Figure 17. Asia Pacific Antibiotics Market: Macrolides, 2019-2030, $ mn 42
Figure 18. Asia Pacific Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn 43
Figure 19. Asia Pacific Antibiotics Market: Quinolones, 2019-2030, $ mn 44
Figure 20. Asia Pacific Antibiotics Market: Monobactam, 2019-2030, $ mn 45
Figure 21. Asia Pacific Antibiotics Market: Aminoglycosides, 2019-2030, $ mn 46
Figure 22. Asia Pacific Antibiotics Market: Carbapenem, 2019-2030, $ mn 47
Figure 23. Asia Pacific Antibiotics Market: Other Drug Classes, 2019-2030, $ mn 48
Figure 24. Breakdown of Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50
Figure 25. Asia Pacific Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%) 50
Figure 26. Asia Pacific Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn 51
Figure 27. Asia Pacific Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn 52
Figure 28. Asia Pacific Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn 53
Figure 29. Asia Pacific Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn 54
Figure 30. Asia Pacific Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn 55
Figure 31. Asia Pacific Antibiotics Market: Other Mechanisms, 2019-2030, $ mn 56
Figure 32. Breakdown of Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58
Figure 33. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%) 58
Figure 34. Asia Pacific Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn 59
Figure 35. Asia Pacific Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn 60
Figure 36. Asia Pacific Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn 61
Figure 37. Breakdown of Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63
Figure 38. Asia Pacific Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%) 63
Figure 39. Asia Pacific Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn 64
Figure 40. Asia Pacific Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn 65
Figure 41. Breakdown of Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 67
Figure 42. Asia Pacific Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%) 67
Figure 43. Asia Pacific Antibiotics Market: Oral Administration, 2019-2030, $ mn 68
Figure 44. Asia Pacific Antibiotics Market: Intravenous Administration, 2019-2030, $ mn 69
Figure 45. Asia Pacific Antibiotics Market: Other Administration Routes, 2019-2030, $ mn 70
Figure 46. Breakdown of Asia Pacific Antibiotics Market by Drug Type, 2019-2030, % of Revenue 71
Figure 47. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%) 72
Figure 48. Asia Pacific Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn 73
Figure 49. Asia Pacific Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn 74
Figure 50. Breakdown of APAC Antibiotics Market by Country, 2019 and 2030, % of Revenue 76
Figure 51. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 77
Figure 52.  Antibiotics Market in Japan, 2019-2030, $ bn 79
Figure 53.  Antibiotics Market in China, 2019-2030, $ bn 81
Figure 54.  Antibiotics Market in Australia, 2019-2030, $ bn 83
Figure 55.  Antibiotics Market in India, 2019-2030, $ bn 85
Figure 56.  Antibiotics Market in South Korea, 2019-2030, $ bn 87
Figure 57.  Antibiotics Market in Rest of APAC, 2019-2030, $ bn 89
Figure 58. Growth Stage of Asia Pacific Antibiotics Industry over the Forecast Period 91

 

Reviews

There are yet no reviews for this product.